India revokes GSK cancer drug patent in latest Big Pharma blow

MUMBAI Fri Aug 2, 2013 5:55pm IST

1 of 3. The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013.

Credit: Reuters/Luke MacGregor/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - India has revoked a patent granted to GlaxoSmithKline Plc(GSK.L) for breast cancer drug Tykerb, a decision that follows a landmark India court ruling disallowing patents for incremental innovations that was a blow to global pharmaceutical firms.

However, the Intellectual Property Appellate Board (IPAB) upheld a patent granted on the original compound, or active pharmaceutical ingredient, lapatinib, citing innovative merit.

As a result, a GSK spokesman said its medicine would remain subject to patent protection until 2019. The additional patent on the particular salt of lapatinib used in Tykerb, which has now been rejected, would have extended that protection to 2021.

India's Supreme Court in April rejected a patent for Novartis AG's (NOVN.VX) cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.

GSK had cut prices of Tykerb by about a third in India as part of a flexible pricing programme designed to make important drugs more affordable in certain emerging markets.

Western drugmakers who covet a bigger share of India's fast-growing $13 billion drugs market have been frustrated by a series of decisions on intellectual property and pricing.

Last year, India revoked patents granted to Pfizer Inc's (PFE.N) cancer drug Sutent, Roche Holding AG's (ROG.VX) hepatitis C drug Pegasys, and Merck & Co's (MRK.N) asthma treatment aerosol suspension formulation. All were revoked on grounds that included lack of innovation.

Fresenius Kabi Oncology FRES.NS, the Indian unit of German healthcare group Fresenius SE (FREG.DE), had challenged patents granted for both the original molecule and its marketed salt version, saying both molecules lacked innovation.

"This decision is just like the landmark Glivec ruling. The IPAB has said that the salt version of lapatinib cannot hold a patent," said lawyer Dominic Alvares of S. Majumdar & Co, which represented Fresenius Kabi in the case.

The IPAB rulings for both the patent disputes were uploaded on its website late on Thursday.

Shares in GlaxoSmithKline Pharmaceuticals (GLAX.NS), the UK company's Indian unit, fell 2.8 percent on Friday.

The company can make an appeal on the decision to India's Supreme Court.

"We are studying the IPAB's decision but maintain our belief in the inventiveness of the lapatinib ditosylate salt and will consider the possibility of taking further steps before the appropriate authorities to validate this," the Indian GSK unit said in an email to Reuters on Friday.

"We are pleased that the IPAB in India has upheld our basic patent for the lapatinib compound, the active ingredient in Tykerb." GSK said. The patent expires in January 2019.

A strip of 10 Tykerb tablets costs about 4,160 rupees in India and a patient is expected to take five tablets a day for 21 days if the cancer is in an advanced stage.

Western pharmaceutical companies, looking to emerging markets such as India to help drive growth, have run into various obstacles recently, ranging from corruption and pricing probes in China to stock management problems in Brazil.

(Additional reporting by Ben Hirschler in London; Editing by Louise Ireland)

FILED UNDER:

Monetary Policy Committee

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage